DuPont Merck licenses ImaRx (US) agent:
This article was originally published in Clinica
Executive Summary
ImaRx (US) has licensed its cardiovascular ultrasound contrast agent, MRX-115, to DuPont Merck. When ImaRx completes Phase II trials, due to start this month, DuPont Merck will assume responsibility for clinical development of the agent. In return for exclusive rights to MRX-115 for cardiology and radiology diagnostic applications in the Americas and cardiology applications in the EU, DuPont Merck will make up-front, milestone and royalty payments. ImaRx will retain rights to radiology applications in the EU and all rights in other regions.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.